Laboratories of Neuro-Oncology/Clinical and Cancer Proteomics, Department of Neurology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
J Neuroimmunol. 2012 Jul 15;248(1-2):40-7. doi: 10.1016/j.jneuroim.2011.11.004. Epub 2011 Nov 29.
Multiple sclerosis is a disabling inflammatory and neurodegenerative disorder that predominantly affects young adults. There is a great need for biomarkers, which could elucidate pathology as well as provide prognosis of disease progression and therapy response in multiple sclerosis. Rapidly evolving, technology driven applications such as mass spectrometry based proteomics are currently being developed for this purpose. In this review, we will outline the current status of the field and detail a number of the bottlenecks as well as future prospects of this type of biomarker research.
多发性硬化症是一种使人丧失能力的炎症性和神经退行性疾病，主要影响年轻人。目前非常需要生物标志物，这些标志物不仅可以阐明疾病的病理，还可以提供多发性硬化症疾病进展和治疗反应的预后。目前正在为此目的开发基于质谱的蛋白质组学等快速发展的技术驱动应用程序。在这篇综述中，我们将概述该领域的现状，并详细介绍此类生物标志物研究的一些瓶颈和未来前景。
